Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer (MATCH)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02725424 |
Recruitment Status :
Completed
First Posted : April 1, 2016
Last Update Posted : August 17, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a randomized, phase II, open-label study. The purpose of this study is to determine the optimal treatment for patients with locally advanced Gastric/Gastroesophageal Cancer according to their HER-2 expression status.
The primary endpoint of this study: major pathology response rate the second endpoints of this study: pathology complete response rate R0 resection rate Progression-free survival ( PFS) Disease -free survival (DFS) Overall survival(OS) Objective response rate(ORR) Adverse event(AE)
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastric Cancer | Drug: S-1 Drug: Trastuzumab Drug: Oxaliplatin Drug: Docetaxel | Phase 2 |
(HER2, human epidermal growth factor receptor-2) positive patients: After 4 cycles of SOX±Trastuzumab neoadjuvant therapy, patients will continue to accept D2 surgery. The patients with R0 resection will continue to receive 4 cycles of SOX±Trastuzumab adjuvant chemotherapy. If the patients are confirmed with tumor progression before surgery, the treatment such as gastrectomy, chemoradiotherapy or second line chemotherapy should be determined by MDT team.
(HER2, human epidermal growth factor receptor-2,HER2) negative patients: After 4 cycles of DOS or SOX regimen as neoadjuvant therapy, patients will continue to accept D2 surgery. The patients with R0 resection will continue to receive then 4 cycles of DOS or SOX adjuvant chemotherapy. If the patients are confirmed with tumor progression before surgery, the treatment such as gastrectomy, chemoradiotherapy or second line chemotherapy should be determined by MDT team.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 180 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Controlled Phase II Study to Compare Preoperative Chemotherapies in Locally Advanced Gastric/Gastroesophageal Cancer |
Actual Study Start Date : | August 2015 |
Actual Primary Completion Date : | December 2018 |
Actual Study Completion Date : | June 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Her2 Positive with SOX
Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA <1.25m2) ,100mg/day (BSA ≥1.25m2, <1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
|
Drug: S-1
Her-2 Positive patients with SOX Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Other Name: Oxaliplatin Drug: Oxaliplatin Her-2 Positive patients with SOX Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Other Name: S-1 |
Experimental: Her2 Positive with SOXT
Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA <1.25m2) ,100mg/day (BSA ≥1.25m2, <1.5 m2), 120mg/day (BSA ≥1.5m2), trastuzumab 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1, every 3 weeks.
|
Drug: S-1
Her-2 Positive patients with SOX Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Other Name: Oxaliplatin Drug: Trastuzumab Her-2 positive patients with SOXT Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
Other Names:
Drug: Oxaliplatin Her-2 Positive patients with SOX Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Other Name: S-1 |
Active Comparator: Her2 Negative with SOX
Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA <1.25m2) ,100mg/day (BSA ≥1.25m2, <1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
|
Drug: S-1
Her-2 Positive patients with SOX Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Other Name: Oxaliplatin Drug: Oxaliplatin Her-2 Positive patients with SOX Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Other Name: S-1 |
Experimental: Her2 Negative with DOS
Docetaxel 60 mg/m2, ivgtt, d1; Oxaliplatin 100 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA <1.25m2) , 100mg/day (BSA ≥1.25m2, <1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
|
Drug: S-1
Her-2 Positive patients with SOX Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Other Name: Oxaliplatin Drug: Oxaliplatin Her-2 Positive patients with SOX Oxaliplatin:130 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Other Name: S-1 Drug: Docetaxel Her-2 Negative patients with DOS Docetaxel: 60 mg/m2, iv, d1 Oxaliplatin:100 mg/m2, iv, d1 S-1:twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
Other Names:
|
- major Pathological response rate [ Time Frame: 40 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Pathologically confirmed gastric cancer or gastroesophageal junction adenocarcinoma;
-
The HER2 receptor protein status should be assessed using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH);
- HER2 positive: IHC 3+ or IHC 2+/ FISH amplification.
- HER2 negative: IHC 0, 1+ or IHC 2+/ FISH without amplification.
- T3-4, any N stage, M0 of gastric or gastro-esophageal junction adenocarcinoma;
- Chemotherapy and radiotherapy naïve.
- Age ≥18 years;
- ECOG(Eastern Cooperative Oncology Group ) 0-1;
- Adequate hematological, hepatic and renal functions: absolute neutrophil count (ANC) ≥ 2.0 G/L, hemoglobin ≥ 90g/L, platelet ≥ 100 G/L; ALT and AST <1.5 times x upper limit of normal (ULN);serum total bilirubin < 1.0 x ULN; serum creatinine < 1.0 x ULN;
- Left ventricular ejection fraction>50%
- Written informed consent.
Exclusion criteria:
- Other pathology Type Other than adenocarcinoma, such as squamous cell carcinoma
- History of allergies to drugs in the study
- Intraperitoneal dissemination or distant metastasis
- Digestive tract obstruction or uncontrollable recurrent bleeding ,clinical significant ascites
- Dysphagia
- Any cause of cirrhosis
- Cardiac function NYHA(New York Heart Association) >I degrees
- Previous myocardial infarction, unstable angina, stroke ,or uncontrollable Arrhythmia
- Any surgical contraindication
- Any chemotherapy or radiotherapy history
- Any surgical resection history of gastric cancer
- History of any other tumors except cured cutaneum carcinoma or carcinoma in situs of cervix
- Any contraindication for chemotherapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02725424
China, Beijing | |
Chinese Academy of Medical Sciences | |
Beijing, Beijing, China, 10000 |
Principal Investigator: | Ping Ai Zhou, MD | Chinese Academy of Medical Sciences |
Responsible Party: | Aiping Zhou, Chief physician, Chinese Academy of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT02725424 |
Other Study ID Numbers: |
CH-GI-071 |
First Posted: | April 1, 2016 Key Record Dates |
Last Update Posted: | August 17, 2022 |
Last Verified: | August 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Docetaxel |
Oxaliplatin Trastuzumab Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological |